Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Tango Therapeutics (NASDAQ: TNGX) is scheduled to participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) is scheduled to participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference on November 10, 2026.
President and CEO Malte Peters will join a fireside chat at 8:00 AM EST. A live webcast will be available through Events & Presentations on the company’s Investors page, with a replay archived for 90 days following the presentation.
Details
News Market Reaction – TNGX
On Nov 3, the day this news came out, TNGX closed 6.48% above the previous close. Argus tracked a peak move of +5.9% during that session. Our momentum scanner recorded 59 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango Therapeutics is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues. For more information, please visit www.tangotx.com.
Investors:
Elizabeth Hickin
ehickin@tangotx.com
Media:
1AB
Amanda Lazaro
amanda@1abmedia.com
